The first and only oral ADT indicated in advanced prostate cancer*,1

Now
available

Now
available

Dive
Into the
Orgovyx®

Data

ORGOVYX® (relugolix tablets, 120 mg) is indicated for the treatment of adult patients with advanced prostate cancer.2

Data

EFFICACY PROFILE

Evaluate the ORGOVYX® efficacy data from the HERO study:

Testosterone suppression
data (Day 29 to Week 48)
Learn More
Testosterone suppression
data at Day 15
Learn More
Testosterone recovery dataLearn More
Health icon

SAFETY PROFILE

Evaluate the safety profile from the HERO study.

Learn More
ORGOVYX® pill

DOSING AND
ADMINISTRATION

Find dosing and administration information related to ORGOVYX®.

About ORGOVYX®
People

HERO STUDY

Learn more about the HERO study, which evaluated ORGOVYX® in advanced prostate cancer patients.

Learn More
Books

Resources

Access relevant information and additional resources for you and your patients.

Explore
Sumitomo Logo

is a trademark of Sumitomo Pharma Co., Ltd., used under license.

SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license.

SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license.

ORGOVYX® and its associated logo are registered trademarks of Sumitomo Pharma Switzerland GmbH.

© 2024 Sumitomo Pharma Canada, Inc. All rights reserved. RGX-CA-00013-24

IMC LogoPAAB Logo